Aeglea BioTherapeutics, Inc. (AGLE) stock declined over -2.30% intraday to trade at $0.51 a share on NASDAQ. The stock opened with a loss of -5.90% at $0.53 and touched an intraday high of $0.538, falling -1.35% against the last close of $0.517. The stock went to a low of $0.504 during the session.
Number of Shares
Cash Flow per Share
Free Float in %
Sales or Revenue18.74 Million
5Y Sales Change32.30%
Fiscal Year Ends2021-12-30
Aeglea BioTherapeutics, Inc., a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases. The company's lead product candidate is pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency. It also develops AGLE-177, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria. In addition, the company's preclinical pipeline includes AGLE-325 for the treatment of cystinuria, as well as other research programs. The company was formerly known as Aeglea BioTherapeutics Holdings, LLC and changed its name to Aeglea BioTherapeutics, Inc. in March 2015. Aeglea BioTherapeutics, Inc. was founded in 2013 and is headquartered in Austin, Texas.
Aeglea BioTherapeutics, Inc. (NASDAQ: AGLE) stock price is $0.51 as of the last check on Thursday, June 30. During the trading session, AGLE stock reached the peak price of $0.538 while $0.504 was the lowest point it dropped to.
The NASDAQ listed AGLE is part of Biotechnology industry that operates in the broader Health Care sector. Aeglea BioTherapeutics, Inc. , a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of patients and families with rare metabolic diseases.
Mr. Jonathan D. Alspaugh M.B.A.
Chief Financial Officer
Mr. Steven Weber
VP, Principal Accounting Officer & Corp. Controller
Dr. Anthony G. Quinn FRCP, M.B Ch.B., M.D., Ph.D.
Pres, CEO & Director
Dr. Leslie S. Sloan Ph.D.
Chief Operating Officer
AGLE stock traded closed the last session at $0.505, which is $-0.01 or -2.30% lower than its previous close of $0.517. AGLE's current trading price is -0.96% lower than its 52-week high of $8.50 where as its distance from 52-week low of 0.51% is -94.06%.
Number of AGLE employees currently stands at -. AGLE operates from 805 Las Cimas Parkway, Suite 100, Austin, TX 78746, United States.
Official Webiste of $AGLE is: https://www.aeglea.com
AGLE stock volume for the day was 354,554 shares while in the previous session number of AGLE shares traded was 354,435 . The average number of AGLE shares traded daily for last 3 months was 919.4 Thousands.
The percentage change in AGLE stock occurred in the recent session was -2.30% while the dollar amount for the price change in AGLE stock was $-0.01.
In the recent session, the day high for AGLE stock was $0.538 while the low for AGLE stock touched on the day was $0.504.
The market value of AGLE currently stands at 34.54 Million with its latest stock price at $0.51 and 66 Million of its shares outstanding.